CVS Health Corp. (NYSE: CVS), the nation’s largest pharmacy chain, has staged a remarkable comeback after years of being overlooked by investors, with its shares surging approximately 24% over the past month. The sharp rally has been driven by a better-than-expected first-quarter earnings report, a turnaround in its previously worst-performing business segment, and subsequent upgrades from Wall Street analysts.
Market analysts believe the integrated healthcare giant is undergoing a fundamental improvement in its business fundamentals, with its long-term investment value finally gaining recognition from investors.
The company reported first-quarter revenue of $100.4 billion, representing a 6.2% year-over-year increase, while earnings per share (EPS) reached $2.30, a staggering 62% jump from the same period last year. Both key metrics significantly exceeded Wall Street consensus estimates, which had called for revenue of $94.4 billion and EPS of $1.93.
The strong performance led CVS to raise its full-year 2026 guidance across the board. The company now expects full-year EPS to range between $6.24 and $6.44, representing a 4.9% increase at the midpoint. Adjusted EPS is projected to be between $7.30 and $7.50, up 4.2% at the midpoint. Additionally, CVS raised its full-year operating cash flow forecast from $9 billion to at least $9.5 billion, signaling increased confidence from management in its future prospects.
As a comprehensive healthcare company combining pharmacy retail, insurance services, and pharmacy benefits management (PBM), CVS has built a unique vertically integrated healthcare ecosystem that pure-play retailers like Walgreens Boots Alliance and pure-play insurers like Humana cannot easily replicate. All three of its business segments posted revenue growth in the quarter, with the previously underperforming insurance division emerging as the biggest bright spot.
The healthcare benefits segment, which includes Aetna, generated revenue of $35.9 billion, up 3.3% year over year. More importantly, the segment’s profitability improved dramatically, with the medical benefit ratio (MBR) — the percentage of premiums spent on medical claims — falling sharply to 84.6% from 87.3% in the prior-year quarter. This improvement was driven by successful efforts to control rising medical utilization costs and the company’s decision to exit money-losing Affordable Care Act (ACA) individual exchanges in 2026, sacrificing low-margin membership volume to boost overall insurance profitability.
The other two segments also delivered solid results. The pharmacy and consumer wellness segment posted a modest revenue increase, benefiting from higher prescription volumes and assets acquired from the ongoing closure of Rite Aid stores. The health services segment, which includes PBM business Caremark, was the strongest performer, with revenue rising 11% year over year to $48.2 billion.
Beyond the operational improvements, CVS’s generous dividend yield remains a key attraction for long-term investors. At current share prices, the company offers a dividend yield of approximately 2.8%, more than double the average dividend yield of the S&P 500 index. Consistent and robust free cash flow generation provides a solid foundation for the dividend payout, with operating cash flow hovering between $9 billion and $10.5 billion in recent fiscal years.
Market analysts note that CVS’s vertically integrated model allows it to capture margins at multiple points along the healthcare value chain, creating a formidable competitive moat. As profitability continues to recover across its business segments, the company’s valuation is expected to undergo further re-rating. The average analyst price target for CVS stands at $101.58, indicating broad market consensus that the stock still has significant upside potential.
While the company’s fundamentals are clearly improving, investors should remain mindful of its elevated debt levels. CVS’s capital-intensive strategy of building its healthcare network through large-scale acquisitions has left it with a substantial debt burden. As of the end of the first quarter, the company had $86.4 billion in long-term debt and total debt of $175 billion. High interest expenses limit the amount of capital available for business expansion and share repurchases.
That said, the company is actively working to reduce its debt load, with total debt declining 1.5% year over year. Market participants generally expect the debt situation to improve gradually as the company’s profitability continues to strengthen.
Overall, CVS Health appears to have found a sustainable path to long-term margin improvement. The recent stock rally is not a short-term speculative move but rather a fundamental revaluation driven by tangible business improvements. While the debt overhang will take time to resolve, the growing synergies between its three business segments make CVS a compelling high-dividend defensive growth stock worthy of long-term investor attention.
